Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 3/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14279606 | 1.00 | KCNA5 (0.49) | KCNA5KDM4AHDAC10HDAC6SYK | |
| SCHEMBL6727710 | 0.81 | TSHR (0.36) | KCNA5LMNAMAPTMEN1HTT | |
| SCHEMBL25762436 | 0.80 | KCNA5 (0.56) | KCNA5KDM4AHDAC10HDAC6SYK | |
| SCHEMBL15631925 | 0.78 | LMNA (0.47) | KCNA5KDM4ASYKLMNAMAPT | |
| SCHEMBL16005902 | 0.77 | KCNA5 (0.54) | KCNA5KDM4AHDAC10HDAC6LMNA | |
| SCHEMBL1808874 | 0.77 | KCNA5 (0.56) | KCNA5KDM4AHDAC10HDAC6SYK | |
| SCHEMBL8018113 | 0.76 | KCNA5 (0.56) | KCNA5KDM4AHDAC10HDAC6SYK | |
| SCHEMBL30159605 | 0.76 | KCNA5 (0.56) | KCNA5KDM4AHDAC10HDAC6SYK | |
| SCHEMBL2158784 | 0.76 | KCNA5 (0.55) | KCNA5KDM4AHDAC10HDAC6LMNA | |
| SCHEMBL26659635 | 0.76 | KCNA5 (0.55) | KCNA5KDM4AHDAC10HDAC6SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314879-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7169777-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1469851-B1 | MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050075344-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2005-04-07 | — | — | US | disclosed |
| EP-1469851-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1358163-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003061660-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002059095-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075344-A1 | Melanocortin receptor agonists | MC4R, MC1R, MC5R | KCNA5 1844/4885KDM4A 3710/4885HDAC10 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.